PHARMExcel at 15: Looking forward

Our journey over the past year has been marked by significant achievements. Receiving honours at the Oxford Business Awards (OBN) and the prestigious Scrip Life Sciences Awards is a testament to the unwavering commitment of our team to deliver excellence in clinical research. These nominations reflect not just the quality of our work but also the values that drive PHARMExcel: honesty and integrity, teamwork, and passion in our mission to make a difference in patient health.

We’ve also hit several key milestones in our studies last year, reaching the end of study for one of our early phase, respiratory trials, completing the last patient last visit for a FIH Obesity study and successfully achieving regulatory approvals, and opening several European centres for an oncology trial. Our work will contribute to furthering our understanding of these disease areas and leading to potential new treatment options.

Also a notable achievement for PHARMExcel is the award for Gold accreditation in Investors in People, highlights our people-centric CRO approach, fostering an environment that values our employee well-being and professional development.

Last year, we forged a meaningful partnership with a leading rare disease research group, underscoring our commitment to supporting under-served patient populations. This collaboration has enabled us to contribute to research that has the potential to transform lives, a mission that lies at the heart of what we do.

We also had the privilege of attending and contributing to several key industry events in 2024, including The Research and Development Forum in Wales, a conference close to my heart, the Advance Therapies Congress at London Excel and the World Orphan Drug Congress in Barcelona . These opportunities not only allowed us to share our insights and expertise but also reinforced PHARMExcel’s position as a thought leader in the industry.

Marking 15 years as a company has been an incredible milestone. Reflecting on our journey from a small CRO with big ambitions, to the internationally respected organisation we are today has been deeply rewarding.

It’s a moment to credit the people who have been part of this journey—our dedicated team, loyal clients, and supportive partners. But most of all I must thank our patients and their families. Without your participation, in often challenging clinical trials, none of this would be possible. You remind us daily as to why we do this. So, thank you.

As we enter 2025, the future looks bright. We’ll continue to innovate, embracing new technologies to streamline trial processes and provide further enhancements for our clients, alongside our international expansion.

Our partnerships remain central to our vision, and we will deepen our focus on areas like rare diseases, advanced therapies and medical devices, ensuring that we remain at the forefront of delivering life-changing therapies and interventions.

The UK will always be prevalent in our approach, and we will continue to support the trial endeavours of our amazing NHS and academic scientists and researchers, many of whom have been responsible for groundbreaking advancements in drug discovery.

And lastly, we have laid the groundwork for implementation of a revised Clinical Trial Quality Assurance strategy that will set new standards for compliance and quality, supporting our audit and vendor management systems and which will sit alongside and complement our clinical delivery.

I want to take this opportunity to thank all the PHARMExcel team and our partners for your unwavering dedication and passion. You are the heart of our success, and I am continually inspired by what we achieve together.

As we look forward to 2025, I want us to carry the momentum of this exceptional year into the future. Here’s to continued growth and making a lasting impact for meaningful clinical research.